155 related articles for article (PubMed ID: 32744151)
21. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M; Colombetti S; Herter S; Sam J; Perro M; Chen S; Bianchi R; Richard M; Schoenle A; Nicolini V; Diggelmann S; Limani F; Schlenker R; Hüsser T; Richter W; Bray-French K; Hinton H; Giusti AM; Freimoser-Grundschober A; Lariviere L; Neumann C; Klein C; Umaña P
Clin Cancer Res; 2018 Oct; 24(19):4785-4797. PubMed ID: 29716920
[No Abstract] [Full Text] [Related]
22. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Tipton TR; Roghanian A; Oldham RJ; Carter MJ; Cox KL; Mockridge CI; French RR; Dahal LN; Duriez PJ; Hargreaves PG; Cragg MS; Beers SA
Blood; 2015 Mar; 125(12):1901-9. PubMed ID: 25631769
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis.
Roodselaar J; Zhou Y; Leppert D; Hauser AE; Urich E; Anthony DC
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33653962
[TBL] [Abstract][Full Text] [Related]
24. Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies.
Grandjean CL; Montalvao F; Celli S; Michonneau D; Breart B; Garcia Z; Perro M; Freytag O; Gerdes CA; Bousso P
Sci Rep; 2016 Oct; 6():34382. PubMed ID: 27698437
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
Church AK; VanDerMeid KR; Baig NA; Baran AM; Witzig TE; Nowakowski GS; Zent CS
Clin Exp Immunol; 2016 Jan; 183(1):90-101. PubMed ID: 26307241
[TBL] [Abstract][Full Text] [Related]
26. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
[TBL] [Abstract][Full Text] [Related]
27. Low binding affinity and reduced complement-dependent cell death efficacy of ofatumumab produced using a plant system (Nicotiana benthamiana L.).
Jin N; Lee JW; Heo W; Ryu MY; So MK; Ko BJ; Kim HY; Yoon SM; Lee J; Kim JY; Kim WT
Protein Expr Purif; 2019 Jul; 159():34-41. PubMed ID: 30880170
[TBL] [Abstract][Full Text] [Related]
28. Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis.
Constantinides M; Fayd'herbe De Maudave A; Potier-Cartereau M; Campos-Mora M; Cartron G; Villalba M
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831451
[TBL] [Abstract][Full Text] [Related]
29. False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay.
Chen K; Page JG; Schwartz AM; Lee TN; DeWall SL; Sikkema DJ; Wang C
J Immunol Methods; 2013 Aug; 394(1-2):22-31. PubMed ID: 23639298
[TBL] [Abstract][Full Text] [Related]
30. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.
Evers M; Ten Broeke T; Jansen JHM; Nederend M; Hamdan F; Reiding KR; Meyer S; Moerer P; Brinkman I; Rösner T; Lebbink RJ; Valerius T; Leusen JHW
MAbs; 2020; 12(1):1795505. PubMed ID: 32744145
[TBL] [Abstract][Full Text] [Related]
31. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
Beum PV; Lindorfer MA; Beurskens F; Stukenberg PT; Lokhorst HM; Pawluczkowycz AW; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2008 Jul; 181(1):822-32. PubMed ID: 18566448
[TBL] [Abstract][Full Text] [Related]
32. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
[TBL] [Abstract][Full Text] [Related]
33. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
[TBL] [Abstract][Full Text] [Related]
34. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Reddy V; Dahal LN; Cragg MS; Leandro M
Drug Discov Today; 2016 Aug; 21(8):1330-8. PubMed ID: 27343722
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
[TBL] [Abstract][Full Text] [Related]
36. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
37. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
[TBL] [Abstract][Full Text] [Related]
38. A tale of two antibodies: obinutuzumab versus rituximab.
Freeman CL; Sehn LH
Br J Haematol; 2018 Jul; 182(1):29-45. PubMed ID: 29741753
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
40. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
